For adults and children with hemophilia A
The first and only recombinant Factor VIII that delivers proven, long-lasting bleed protection with a novel single-chain design.
AFSTYLA offers dosing 2 or 3 times a week so you and your doctor have more flexibility in choosing a schedule that works for you.
FDA-approved for dosing 2 or 3 times a week.
Zero median annualized spontaneous bleeds* were reported in both children and adults regardless of dosing schedule (2 or 3 times a week).
In clinical trials, whether dosed 2 or 3 times a week.
*Annualized spontaneous bleeding rate in clinical trials (interquartile range [IQR]=0–2.4 for patients ≥12 years; 0–2.2 for patients <12 years).
AFSTYLA uses a novel single-chain design to enhance molecular stability in the bloodstream and provide long-lasting bleed protection.
Once activated, AFSTYLA is identical to natural Factor VIII.
*Annualized spontaneous bleeding rate in clinical trials(interquartile range [IQR]=0–2.4 for patients ≥12 years; 0–2.2 for patients <12 years).
Sign up today
CSL Behring makes it easy to start on AFSTYLA with a simple 3-step process. You’ll also have access to comprehensive support services that can make a meaningful difference in the lives of people with bleeding disorders.
You can also call 1-800-676-4266 to get detailed information about the services available to you.